CVRX
CVRx, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$3.05
+1.33%Sep 1, 2026, 21:48 UTC
Pomerantz LLP announced an investigation into CVRx, Inc. for potential securities fraud or unlawful business practices on behalf of investors.
Source:Aug 24, 2026, 12:30 UTC
Jorey Chernett, beneficial owner of more than 5.5% of CVRx's outstanding shares, delivered a letter to the CVRx Board urging it to launch an immediate process to sell the company to a strategic acquirer.
Source:Aug 24, 2026, 12:30 UTC
CVRx announced that Devoted Health issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026, covering approximately 466,000 members across 29 states.
Source:Aug 13, 2026, 07:03 UTC
CVRx announced the launch of the BENEFIT-HF post-market clinical trial for its Barostim therapy.
Source:Aug 11, 2026, 00:00 UTC
CVRx, Inc. terminated Robert John as Chief Revenue Officer, effective August 10, 2026, and appointed Paul Verrastro as Interim Head of Sales, effective August 11, 2026.
Aug 7, 2026, 15:56 UTC
Johnson Fistel, PLLP announced an investigation into CVRx, Inc. and certain executive officers for potential violations of state or federal securities laws related to investor losses.
Source:Aug 6, 2026, 20:05 UTC
CVRx, Inc. announced its financial and operating results for the second quarter of 2026 on August 6, 2026.
Jun 9, 2026, 00:00 UTC
Jared Oasheim resigned as Chief Financial Officer of CVRx, Inc., effective June 8, 2026, with transition support and consulting arrangements through February 2027.
Source: